STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes

Science Signaling

Volumn 7, Issue 310, 2014, Pages

  Xiang, Michael ^a   Birkbak, Nicolai J ^b,e   Vafaizadeh, Vida ^c   Walker, Sarah R ^a,b   Yeh, Jennifer E ^a   Liu, Suhu ^a   Kroll, Yasmin ^a   Boldin, Mark ^d,f   Taganov, Konstantin ^d,g   Groner, Bernd ^c   Richardson, Andrea L ^b   Frank, David A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^d CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g MILLIPORE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERLEUKIN-6; MICRORNAS; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; RNA, NEOPLASM; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84894495362     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004497     Document Type: Article

References (59)

1. D. A. Frank, STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251, 199-210 (2007).
2. P. Sansone, J. Bromberg, Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J. Clin. Oncol. 30, 1005-1014 (2012).
3. M. Hedvat, D. Huszar, A. Herrmann, J. M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C. M. Kowolik, H. Xin, B. Armstrong, G. Bebernitz, S. Weng, L. Wang, M. Ye, K. McEachern, H. Chen, D. Morosini, K. Bell, M. Alimzhanov, S. Ioannidis, P. McCoon, Z. A. Cao, H. Yu, R. Jove, M. Zinda, The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009).
4. D. R. Hodge, E. M. Hurt, W. L. Farrar, The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41, 2502-2512 (2005).
5. S. Grivennikov, M. Karin, Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer Cell 13, 7-9 (2008).
6. T. A. Libermann, D. Baltimore, Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol. Cell. Biol. 10, 2327-2334 (1990).
7. D. Iliopoulos, H. A. Hirsch, K. Struhl, An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706 (2009).
8. D. Iliopoulos, S. A. Jaeger, H. A. Hirsch, M. L. Bulyk, K. Struhl, STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39, 493-506 (2010).
9. M. N. Ndlovu, C. Van Lint, K. Van Wesemael, P. Callebert, D. Chalbos, G. Haegeman, W. Vanden Berghe, Hyperactivated NF-κB and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol. Cell. Biol. 29, 5488-5504 (2009).
10. G. Matsumoto, J. Namekawa, M. Muta, T. Nakamura, H. Bando, K. Tohyama, M. Toi, K. Umezawa, Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 11, 1287-1293 (2005).
11. W. Xiao, D. R. Hodge, L. Wang, X. Yang, X. Zhang, W. L. Farrar, Co-operative functions between nuclear factors NFκB and CCAT/enhancer-binding protein-β (C/EBP-β) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 61, 354-370 (2004).
12. J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, C. Montagut, M. Tapia, C. Campás, L. Dang, M. Rolfe, J. S. Ross, P. Gascon, J. Albanell, B. Mellado, Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin. Cancer Res. 12, 5578-5586 (2006).
13. J. Yang, S. Kantrow, J. Sai, O. E. Hawkins, M. Boothby, G. D. Ayers, E. D. Young, E. G. Demicco, A. J. Lazar, D. Lev, A. Richmond, Ikk4a/Arf inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer Res. 72, 4682-4695 (2012).
14. S. Grivennikov, E. Karin, J. Terzic, D. Mucida, G. Y. Yu, S. Vallabhapurapu, J. Scheller, S. Rose-John, H. Cheroutre, L. Eckmann, M. Karin, IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
15. J. Liang, M. Nagahashi, E. Y. Kim, K. B. Harikumar, A. Yamada, W. C. Huang, N. C. Hait, J. C. Allegood, M. M. Price, D. Avni, K. Takabe, T. Kordula, S. Milstien, S. Spiegel, Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23, 107-120 (2013).
16. D. P. Bartel, MicroRNAs: Target recognition and regulatory functions. Cell 136, 215-233 (2009).
17. D. Löffler, K. Brocke-Heidrich, G. Pfeifer, C. Stocsits, J. Hackermüller, A. K. Kretzschmar, R. Burger, M. Gramatzki, C. Blumert, K. Bauer, H. Cvijic, A. K. Ullmann, P. F. Stadler, F. Horn, Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110, 1330-1333 (2007).
18. M. Brock, M. Trenkmann, R. E. Gay, B. A. Michel, S. Gay, M. Fischler, S. Ulrich, R. Speich, L. C. Huber, Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ. Res. 104, 1184-1191 (2009).
19. B. Dai, J. Meng, M. Peyton, L. Girard, W. G. Bornmann, L. Ji, J. D. Minna, B. Fang, J. A. Roth, STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 71, 3658-3668 (2011).
20. M. Hatziapostolou, C. Polytarchou, E. Aggelidou, A. Drakaki, G. A. Poultsides, S. A. Jaeger, H. Ogata, M. Karin, K. Struhl, M. Hadzopoulou- Cladaras, D. Iliopoulos, An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 147, 1233-1247 (2011).
21. J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, J. E. Darnell Jr., Stat3 as an oncogene. Cell 98, 295-303 (1999).
22. T. N. Dechow, L. Pedranzini, A. Leitch, K. Leslie, W. L. Gerald, I. Linkov, J. F. Bromberg, Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. U.S.A. 101, 10602-10607 (2004).
23. L. M. Neilson, J. Zhu, J. Xie, M. G. Malabarba, K. Sakamoto, K. U. Wagner, R. A. Kirken, H. Rui, Coactivation of Janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: Recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol. Endocrinol. 21, 2218-2232 (2007).
24. K. D. Taganov, M. P. Boldin, K. J. Chang, D. Baltimore, NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 103, 12481-12486 (2006).
25. - stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-2735 (2011).
26. H. Xiong, J. Hong, W. Du, Y. W. Lin, L. L. Ren, Y. C.Wang, W. Y. Su, J. L. Wang, Y. Cui, Z. H. Wang, J. Y. Fang, Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. 287, 5819-5832 (2012).
27. A. Kontzias, A. Kotlyar, A. Laurence, P. Changelian, J. J. O'Shea, Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease. Curr. Opin. Pharmacol. 12, 464-470 (2012).
28. D. Bhaumik, G. K. Scott, S. Schokrpur, C. K. Patil, J. Campisi, C. C. Benz, Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27, 5643-5671 (2008).
29. D. R. Hurst, M. D. Edmonds, G. K. Scott, C. C. Benz, K. S. Vaidya, D. R. Welch, Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 69, 1279-1283 (2009).
30. M. Katakowski, X. Zheng, F. Jiang, T. Rogers, A. Szalad, M. Chopp, MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest. 28, 1024-1030 (2010).
31. H. Xia, Y. Qi, S. S. Ng, X. Chen, D. Li, S. Chen, R. Ge, S. Jiang, G. Li, Y. Chen, M. L. He, H. F. Kung, L. Lai, M. C. Lin, microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res. 1269, 158-165 (2009).
32. Y. Li, T. G. Vandenboom II, Z. Wang, D. Kong, S. Ali, P. A. Philip, F. H. Sarkar, miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70, 1486-1495 (2010).
33. Z. Hou, L. Xie, L. Yu, X. Qian, B. Liu, MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. Med. Oncol. 29, 886-892 (2012).
34. B. Xu, N. Wang, X. Wang, N. Tong, N. Shao, J. Tao, P. Li, X. Niu, N. Feng, L. Zhang, L. Hua, Z. Wang, M. Chen, MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 72, 1171-1178 (2012).
35. S. L. Lin, A. Chiang, D. Chang, S. Y. Ying, Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14, 417-424 (2008).
36. M. Shao, S. Rossi, B. Chelladurai, M. Shimizu, O. Ntukogu, M. Ivan, G. A. Calin, D. Matei, PDGF induced microRNA alterations in cancer cells. Nucleic Acids Res. 39, 4035-4047 (2011).
37. L. H. Liu, H. Li, J. P. Li, H. Zhong, H. C. Zhang, J. Chen, T. Xiao, miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem. Biophys. Res. Commun. 416, 31-38 (2011).
38. M. Zhang, Q. Liu, S. Mi, X. Liang, Z. Zhang, X. Su, J. Liu, Y. Chen, M. Wang, Y. Zhang, F. Guo, Z. Zhang, R. Yang, Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J. Immunol. 186, 4716-4724 (2011).
39. H. Lee, A. Herrmann, J. H. Deng, M. Kujawski, G. Niu, Z. Li, S. Forman, R. Jove, D. M. Pardoll, H. Yu, Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 15, 283-293 (2009).
40. M. Rokavec, W. Wu, J. L. Luo, IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol. Cell 45, 777-789 (2012).
41. H. Tye, C. L. Kennedy, M. Najdovska, L. McLeod, W. McCormack, N. Hughes, A. Dev, W. Sievert, C. H. Ooi, T. O. Ishikawa, H. Oshima, P. S. Bhathal, A. E. Parker, M. Oshima, P. Tan, B. J. Jenkins, STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22, 466-478 (2012).
42. M. S. Ebert, P. A. Sharp, Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515-524 (2012).
43. Z. Kanaan, S. N. Rai, M. R. Eichenberger, C. Barnes, A. M. Dworkin, C. Weller, E. Cohen, H. Roberts, B. Keskey, R. E. Petras, N. P. Crawford, S. Galandiuk, Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum. Mutat. 33, 551-560 (2012).
44. M. Liu, T. Sakamaki, M. C. Casimiro, N. E. Willmarth, A. A. Quong, X. Ju, J. Ojeifo, X. Jiao, W. S. Yeow, S. Katiyar, L. A. Shirley, D. Joyce, M. P. Lisanti, C. Albanese, R. G. Pestell, The canonical NF-κB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70, 10464-10473 (2010).
45. S. I. Grivennikov, F. R. Greten, M. Karin, Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
46. J. Debnath, S. K. Muthuswamy, J. S. Brugge, Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268 (2003).
47. J. DiRenzo, S. Signoretti, N. Nakamura, R. Rivera-Gonzalez, W. Sellers, M. Loda, M. Brown, Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 62, 89-98 (2002).
48. H. Ouyang, L. J. Mou, C. Luk, N. Liu, J. Karaskova, J. Squire, M. S. Tsao, Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am. J. Pathol. 157, 1623-1631 (2000).
49. E. A. Nelson, S. R. Walker, A. Kepich, L. B. Gashin, T. Hideshima, H. Ikeda, D. Chauhan, K. C. Anderson, D. A. Frank, Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 112, 5095-5102 (2008).
50. S. R. Walker, M. Chaudhury, E. A. Nelson, D. A. Frank, Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol. Pharmacol. 78, 903-908 (2010).
51. S. R. Walker, E. A. Nelson, L. Zou, M. Chaudhury, S. Signoretti, A. Richardson, D. A. Frank, Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol. Cancer Res. 7, 966-976 (2009).
52. S. R. Walker, E. A. Nelson, D. A. Frank, STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 26, 224-233 (2007).
53. T. E. Battle, J. Arbiser, D. A. Frank, The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106, 690-697 (2005).
54. D. A. Frank, S. Mahajan, J. Ritz, B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest. 100, 3140-3148 (1997).
55. J. V. Alvarez, P. G. Febbo, S. Ramaswamy, M. Loda, A. Richardson, D. A. Frank, Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 65, 5054-5062 (2005).
56. S. J. Clark, J. Harrison, C. L. Paul, M. Frommer, High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22, 2990-2997 (1994).
57. J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, S. B. Baylin, Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U.S.A. 93, 9821-9826 (1996).
58. T. E. Battle, D. A. Frank, STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1. Blood 102, 3016-3024 (2003).
59. S. R. Walker, E. A. Nelson, J. E. Yeh, L. Pinello, G. C. Yuan, D. A. Frank, STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol. Cell. Biol. 33, 2879-2890 (2013).